BridgeBio Pharma (BBIO) Stock Price
BridgeBio Pharma Price
Revenue has compounded at 40.5% per year over the past 5 years to 221.9 M USD. BridgeBio Pharma's net margin stands at -241.4%, up from -5,439% several years earlier.
BridgeBio Pharma stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of BridgeBio Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BridgeBio Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BridgeBio Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | BridgeBio Pharma Price |
|---|
BridgeBio Pharma Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
BridgeBio Pharma Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (B USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (B USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|
| 0.22 | 0.51 | 0.93 | 1.59 | 2.29 | 3.15 | 3.83 | 4.54 |
| 2,355.56 | 129.41 | 83.63 | 71.21 | 43.6 | 37.53 | 21.7 | 18.43 |
| 98.64 | 43 | 23.42 | 13.68 | 9.52 | 6.93 | 5.69 | 4.8 |
| 218 | 218 | 218 | 218 | 218 | 218 | 218 | 218 |
| -0.54 | -0.68 | -0.36 | 0.1 | 0.93 | 1.48 | 2.02 | 2.53 |
| -16.8 | 27.1 | -47.35 | -128.77 | 799.03 | 59.61 | 36.94 | 25.2 |
| 186.08 | 186.08 | 186.08 | 186.08 | 186.08 | 186.08 | 186.08 | 186.08 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales BridgeBio Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BridgeBio Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BridgeBio Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares BridgeBio Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BridgeBio Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
BridgeBio Pharma stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
BridgeBio Pharma Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
BridgeBio Pharma business model & stock analysis
BridgeBio Pharma SWOT Analysis
Strengths
BridgeBio Pharma Inc has several strengths that contribute to its competitive advantage:
- Strong executive leadership with extensive experience in the biopharmaceutical industry.
- Robust portfolio of innovative drug candidates targeting various genetic diseases.
- Strategic partnerships with leading academic institutions and research organizations.
- Solid financial position with significant funding and investment support.
- Advanced research and development capabilities, leveraging cutting-edge technologies.
Despite its strengths, BridgeBio Pharma Inc faces certain weaknesses that pose challenges:
- Relatively limited market presence compared to well-established pharmaceutical companies.
- Dependency on the success of clinical trials, with inherent risks of unforeseen outcomes.
- Potential regulatory hurdles and delays in obtaining necessary approvals.
- Limited manufacturing and distribution capabilities, which may impact scalability.
- Potential vulnerability to intellectual property disputes and litigation.
BridgeBio Pharma Inc can leverage the following opportunities to drive growth and expansion:
- Emerging market demand for innovative genetic disease treatments.
- Collaboration opportunities with biotechnology and pharmaceutical companies.
- Potential for strategic acquisitions and partnerships to enhance product pipeline.
- Advancements in genetic research, providing additional targets for drug development.
- Increasing government support and funding for genetic disease research.
BridgeBio Pharma Inc should be aware of the following threats in its operating environment:
- Intense competition from established pharmaceutical companies and emerging biotechs.
- Potential challenges in securing favorable reimbursement and market access.
- Rapidly evolving regulatory landscape, requiring compliance and adaptation.
- Uncertainties surrounding drug pricing and healthcare policies.
- Risks associated with intellectual property infringement and patent expiration.
Weaknesses
Despite its strengths, BridgeBio Pharma Inc faces certain weaknesses that pose challenges:
- Relatively limited market presence compared to well-established pharmaceutical companies.
- Dependency on the success of clinical trials, with inherent risks of unforeseen outcomes.
- Potential regulatory hurdles and delays in obtaining necessary approvals.
- Limited manufacturing and distribution capabilities, which may impact scalability.
- Potential vulnerability to intellectual property disputes and litigation.
BridgeBio Pharma Inc can leverage the following opportunities to drive growth and expansion:
- Emerging market demand for innovative genetic disease treatments.
- Collaboration opportunities with biotechnology and pharmaceutical companies.
- Potential for strategic acquisitions and partnerships to enhance product pipeline.
- Advancements in genetic research, providing additional targets for drug development.
- Increasing government support and funding for genetic disease research.
BridgeBio Pharma Inc should be aware of the following threats in its operating environment:
- Intense competition from established pharmaceutical companies and emerging biotechs.
- Potential challenges in securing favorable reimbursement and market access.
- Rapidly evolving regulatory landscape, requiring compliance and adaptation.
- Uncertainties surrounding drug pricing and healthcare policies.
- Risks associated with intellectual property infringement and patent expiration.
Opportunities
BridgeBio Pharma Inc can leverage the following opportunities to drive growth and expansion:
- Emerging market demand for innovative genetic disease treatments.
- Collaboration opportunities with biotechnology and pharmaceutical companies.
- Potential for strategic acquisitions and partnerships to enhance product pipeline.
- Advancements in genetic research, providing additional targets for drug development.
- Increasing government support and funding for genetic disease research.
BridgeBio Pharma Inc should be aware of the following threats in its operating environment:
- Intense competition from established pharmaceutical companies and emerging biotechs.
- Potential challenges in securing favorable reimbursement and market access.
- Rapidly evolving regulatory landscape, requiring compliance and adaptation.
- Uncertainties surrounding drug pricing and healthcare policies.
- Risks associated with intellectual property infringement and patent expiration.
Threats
BridgeBio Pharma Inc should be aware of the following threats in its operating environment:
- Intense competition from established pharmaceutical companies and emerging biotechs.
- Potential challenges in securing favorable reimbursement and market access.
- Rapidly evolving regulatory landscape, requiring compliance and adaptation.
- Uncertainties surrounding drug pricing and healthcare policies.
- Risks associated with intellectual property infringement and patent expiration.
BridgeBio Pharma Segments
BridgeBio Pharma Revenue by Segment (1/3)
Max
Details
BridgeBio Pharma Revenue by Segment (2/3)
3 Years
5 Years
10 Years
25 Years
Max
Details
BridgeBio Pharma Revenue by Segment (3/3)
Max
Details
BridgeBio Pharma Eulerpool Fair Value
BridgeBio Pharma historical P/E ratio, EBIT multiple, and P/S ratio
BridgeBio Pharma annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
BridgeBio Pharma shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
BridgeBio Pharma Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 4/30/2026 | -0.7USD | 180.77 MUSD | 2026 Q1 |
| 4/27/2026 | -0.7USD | 182.29 MUSD | 2026 Q1 |
| 2/24/2026 | -0.76USD | 149.78 MUSD | 2025 Q4 |
| 2/19/2026 | -0.76USD | 149.78 MUSD | 2025 Q4 |
| 2/18/2026 | -0.76USD | 149.78 MUSD | 2025 Q4 |
| 5/2/2024 | -0.97USD | 1.48 MUSD | 2024 Q1 |
| 2/21/2024 | -0.94USD | 12.05 MUSD | 2023 Q4 |
| 8/2/2023 | -0.81USD | 13.07 MUSD | 2023 Q2 |
| 5/3/2023 | -0.88USD | 9.01 MUSD | 2023 Q1 |
| 2/22/2023 | -0.98USD | 6.31 MUSD | 2022 Q4 |
EESG©
Eulerpool ESG Scorecard© for the BridgeBio Pharma stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
BridgeBio Pharma shareholder structure
| % | Name |
|---|---|
9.22639% | |
8.53862% | |
6.88131% | |
6.17147% | |
4.81373% | |
4.09942% |
BridgeBio Pharma Executives and Management Board
Dr. Neil Kumar
(46)Chief Executive Officer, Director · since 2015
Dr. Thomas Trimarchi
(40)President, Chief Financial Officer
Dr. Charles Homcy
(76)Lead Director, Chairman of Pharmaceuticals · since 2018
Dr. Frank Mccormick
(74)Director · since 2019
Dr. Andrew Lo
(64)Independent Director
Frequently asked questions about BridgeBio Pharma
BridgeBio Pharma Inc is a biopharmaceutical company specializing in the development and commercialization of genetic medicines. The company aims to identify and advance therapies for diseases with clear genetic causes, leveraging its deep understanding of molecular pathways and human biology. BridgeBio Pharma Inc follows a diversified business model, which includes creating subsidiary companies focused on developing treatments for specific genetic diseases. These subsidiaries collaborate with academic institutions and industry partners to expedite the development of innovative therapies. By focusing on genetically driven diseases and utilizing a collaborative approach, BridgeBio Pharma Inc strives to bring transformative treatments to patients in need.
BridgeBio Pharma stock
BridgeBio Pharma Peer Group
BridgeBio Pharma Ticker
BridgeBio Pharma FIGI
All fundamentals and in-depth analysis of BridgeBio Pharma
Our stock analysis for BridgeBio Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BridgeBio Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.